References
- Lind T, Cederberg C, Ekenved G, Haglund U, Olbe L. Effect of omeprazole - a gastric proton pump inhibitor - on pentagastrin stimulated acid secretion in man. Gut 1983; 24: 270–276
- Lind T, Moore M, Olbe L. Intravenous omeprazole: Effect on 24-hour intragastric pH in duodenal ulcer patients. Digestion 1986; 34: 78–86
- Regårdh C-G, Gabrielsson M, Hoffmann K-J, Löfberg I, Skånberg I. Pharmacokinetics and metabolism of omeprazole in animals and man - an overview. Scand J Gastroenterol 1985; 20(suppl 108)79–94
- Pilbrant Å, Cederberg C. Development of an oral formulation of omeprazole. Scand J Gastroenterol 1985; 20(suppl 108)113–120
- Regårdh C-G. Pharmacokinetics and metabolism of omeprazole in man. Scand J Gastroenterol 1986; 21(suppl 118)99–104
- Wallmark B, Brändström A, Larsson H. Evidence for acid-induced transformation of omeprazole into an active inhibitor of (H+ + K+)-ATPase within the parietal cell. Biochim Biophys Acta 1984; 778: 549–558
- Lind T, Andersson T, Skänberg I, Olbe L. Biliary excretion of intravenous (14C) omeprazole in humans. Clin Pharmacol Ther 1987; 42: 504–508
- Naesdal J, Andersson T, Bodemar G, et al. Pharmacokinetics of 14C-omeprazole in patients with impaired renal function. Clin Pharmacol Ther 1986; 40: 344–351
- Mayer U A. Molecular mechanisms of the dibrisoquine- and mephenytoin-polymorphisms: studies at the protein and DNA level and with circulating autoantibodies against P-450 buf 1 (dbl) and P-450 meph. 7th international symposium on microsomes and drug oxidation, J Miners, D J Birkett, R Drew, M McManus. Taylor and Francis, Adelaide, London 1988; 201–208
- Dickins M, Bridges J W. The relationship between the binding of 2-n-alkylbenzimidazoles to rat hepatic microsomal cytochrome P-450 and the inhibition of monooxygenation. Biochem Pharmacol 1982; 31: 1315–1320
- Gugler R, Jensen J C. Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology 1985; 89: 1235–1241
- Henry D, Brent P, Whyte I, Mihaly G, Devenish-Meares S. Propranolol steady-state pharmacokinetics are unaltered by omeprazole. Eur J Clin Pharmacol 1987; 33: 369–373
- Prichard P J, Walt R P, Kitchingman G K, et al. Oral phenytoin pharmacokinetics during omeprazole therapy. Br J Clin Pharmacol 1987; 24: 543–545
- Gugler R, Jensen J C. Drugs other than H2-receptor antagonists as clinically important inhibitors of drug metabolism in vivo. Pharmacol Ther 1987; 33: 133–137
- Sutfin T, Balmér K, Boström H, Eriksson S, Hbglund P, Paulsen O. Stereoselective interaction of omeprazole with warfarin in healthy men. Ther Drug Monit, (in press)
- Henry D A, Somerville K W, Kitchingman G, Langman M JS. Omeprazole: effects on oxidative drug metabolism. Br J Clin Pharmacol 1984; 18: 195–200
- Howden C W, Meredith P A, Forrest J AH, Reid J L. Oral pharmacokinetics of omeprazole. Eur J Clin Pharmacol 1984; 26: 641–643
- Prichard P J, Yeomans N D, Mihaly G W, et al. Omeprazole: A study of its inhibition of gastric pH and oral pharmacokinetics after morning or evening dosage. Gastroenterology 1985; 88: 64–69
- Müller P, Seitz H K, Simon B, Dammann H G. Säuresekretionsverhalten und Plasmaspiegel unter einer mehrtägigen Omeprazole-Gabe. Arznei-mittelforschung 1983; 33: 1685–1686
- Howden C W, Forrest J AH, Reid J L. Effects of single and repeated doses of omeprazole on gastric acid and pepsin secretion in man. Gut 1984; 25: 707–710
- Müller P, Seitz H K, Simon B, et al. Vierwochige Omeprazole-Gabe: Einfluss auf Saureverhalten und basale Hormonspiegel. Z Gastroenterol 1984; 22: 236–240
- Röhss K, Andrén K, Heggelund A, Lagerstrom P O, Lundborg P. Bioavailability of omeprazole given in conjunction with food. Acta Pharmacol Toxicol (Copenh) 1986; 59(suppl 5)85
- Tuynman H ARE, Festen H PM, Rohss K, Meuwissen S GM. Lack of effect of antacids on plasma concentrations of omeprazole given as enteric-coated granules. Br J Clin Pharmacol 1987; 24: 833–835